首页|甲氨蝶呤联合子宫动脉栓塞治疗剖宫产术后疤痕妊娠的疗效

甲氨蝶呤联合子宫动脉栓塞治疗剖宫产术后疤痕妊娠的疗效

扫码查看
目的 探讨甲氨蝶呤注射和子宫动脉栓塞联合治疗对剖宫产术后子宫瘢痕妊娠患者治疗效果和安全性.方法 选取宁波市第一医院产科2016年10月~2017年4月收治的80例患者,随机平均分为观察组与对照组,每组40例;对照组采用甲氨蝶呤化学药物治疗,观察组在此基础上予以子宫动脉栓塞治疗.比较2组的疗效和不良反应.结果 治疗后,观察组患者血清中的β-人体绒毛膜促性腺激素和孕酮的浓度显著降低、治愈率高、住院时间短,以上数据2组相比差异有统计学意义(P<0.05).观察组出现恶心、呕吐等不良反应的患者比例显著低于对照组,2组差异具有统计学意义(P<0.05).结论 甲氨蝶呤注射联合子宫动脉栓塞子宫瘢痕妊娠具有显著的治疗效果,降低不良反应.
Effect of methotrexate combined with uterine artery embolization on the treatment of cesarean section scar pregnancy
Objective To explore the effect and the adverse reaction of methotrexate injection combined with uterine artery embolization on the treatment of the patients with uterine cesarean section scar pregnancy. Methods From October 2016 to April 2017, 80 patients uterine cesarean section scar pregnancy were randomly divided into the observation group and the control group. The control group were received methotrexate, at this basis the observation group were given uterine artery embolization. The effect and adverse reaction in the two groups were compared. Results After treatment, in the observation group serum beta human chorionic gonadotropin and progesterone hormone concentration significantly reduced. In the observation group, the cure rate was higher and the length of stay was shorter. Compared with the control group, the difference of all above the data had statistically significant (P<0.05). Observation group in the proportion of patients with adverse reactions such as nausea, vomiting was significantly lower than control group, two groups statistically significant difference (P<0.05). Conclusion Methotrexate combined with uterine artery embolization on the treatment of uterine scar pregnancy has significant curative effect, which can reduce the adverse reactions of chemotherapy drugs and shorten the length of stay in hospital.

methotrexateuterine artery embolizationuterine scar pregnancy

唐文波、吴安乐

展开 >

宁波市第一医院 产科,浙江 宁波 315000

宁波市第一医院 放射科,浙江 宁波 315000

甲氨蝶呤 子宫动脉栓塞 子宫瘢痕妊娠

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(11)
  • 6